Oncology

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Novo Nordisk’s Concizumab for Hemophilia; AbbVie Ends its Alliance with Alector; ADC Therapeutics and Sobi Enters in Exclusive Licensing Deal; BMS’ Opdivo Gets NHS Use; Merck to Acquire Seagen; FDA Priority Review to Roche’s Lunsumio; AstraZeneca to Acquire TeneoTwo; FDA Orphan Drug Designation to PBI-200

Novo Nordisk Reports Phase III Results of Concizumab Drug for Hemophilia A or B Novo Nordisk has announced Phase III results for their concizumab drug for hemophilia A or B, demonstrating efficacy in preventing bleeding events and paving the way for regulatory filings later this year. Concizumab, an anti-tissue factor pathway inhibitor (TFPI) antibody, reduced the number of treated bleeds in patients by 86% when given as a once-daily subcutaneous injection in the Explorer7 trial. The findings were presented at the International Society on Thrombosis and Haemostasis (ISTH) annual meeting. It also achieved a median annualized bleed rate (ABR) of 0.0, compared to 9...

Explore More...